Researchers in Japan have developed a new mass spectrometry method that enables better profiling of phosphoinositides, a family of membrane lipids that is essential for many biological and pathological processes and has been implicated in the pathogenesis of various diseases.

Profiling of phosphoinositide acyl variants and their roles in biological changes has been difficult due to their complexity and low intracellular concentrations. Previous methods have produced results that cannot be easily applied to clinical or pathological samples from experimental animals. Even newer methods using mass spectrometry have struggled to simultaneously quantify the acyl variants of individual regioisomers in samples. 

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

However, a new method developed by Tokyo Medical and Dental University has provided new insights into the structure and dynamics of phosphoinositide acyl variants, both in intracellular and extracellular environments. They call the method Phosphoinositide Regioisomer Measurement by Chiral column chromatography and Mass Spectrometry (PRMC-MS).

The method allows for simultaneous measurement of all eight classes of phosphoinositides in a single sample. Its high sensitivity also allows for the detection of tiny but important changes in intracellular phosphoinositide levels, yielding data that shows that it can be applied to blood samples to track phosphoinositide signatures potentially related to disease states.

PRMC-MS also enables analysis of phosphoinositide acyl variants in different types of biological samples, such surgical specimens. This can reveal previously unrecognized disturbances of phosphoinositide fatty acyl profiles in cancerous tissue and monitoring of their extracellular mobilization.

Further study of the differing acyl variants and their conferring of protein binding properties could reveal how they activate a signaling pathway that favors cancer cell growth and survival and emerge as a target for cancer therapy.  

In tissue and liquid biopsies, use of PRMC-MS to evaluate phosphoinositide signatures at the acyl variant level could also reveal biomarkers suitable for a wide variety of clinical applications.

The method is described in more detail in a recent issue of Nature Communications.